

Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond

Deepak Kumar,¹ Sulgey Gauthami,² Jagadeesh Bayry,^{3,4} Srinivas V. Kaveri,^{3,5} and Nagendra R. Hegde²

The dawn of the 20th century saw the formative years of developments in immunology. In particular, immunochemistry, specifically pertaining to antibodies, was extensively studied. These studies laid the foundations for employing antibodies in a variety of ways. Not surprisingly, antibodies have been used for applications ranging from biomedical research to disease diagnostics and therapeutics to evaluation of immune responses during natural infection and those elicited by vaccines. Despite recent advancements in cellular immunology and the excitement of T cell therapy, use of antibodies represents a large proportion of immunotherapeutic approaches as well as clinical interventions. Polyclonal antibodies in the form of plasma or sera continue to be used to treat a number of diseases, including autoimmune disorders, cancers, and infectious diseases. Historically, antisera to toxins have been the longest serving biotherapeutics. In addition, intravenous immunoglobulins (IVIg) have been extensively used to treat not only immunodeficiency conditions but also autoimmune disorders. Beyond the simplistic suppositions of their action, the IVIg have also unraveled the immune regulatory and homeostatic ramifications of their use. The advent of monoclonal antibodies (MAbs), on the other hand, has provided a clear pathway for their development as drug molecules. MAbs have found a clear place in the treatment of cancers and extending lives and have been used in a variety of other conditions. In this review, we capture the important developments in the therapeutic applications of antibodies to alleviate disease, with a focus on some of the recent developments.

Keywords: antibodies, therapy, cancer, infectious disease

Introduction

ANTIBODIES ARE INDISPENSABLE components of the immune system. The tryst of antibodies with therapeutic applications began with Emil von Behring and Paul Ehrlich at the end of the 19th century into the 20th century. Combined with the seminal work of Karl Landsteiner and the exemplary contributions of a host of other scientists, the early part of the 20th century set the stage for the understanding of antibodies as biochemical molecules and their functional characteristics. Further, hybridoma technology provided the much-needed impetus to take antibodies to a whole new level of wide-ranging applications in medical interventions. Antibodies are now a versatile tool for diagnostics and therapy of various conditions in humans and animals.

Serum/Plasma Therapy

Serum or plasma therapy involves the passive transfer of pre-existing or pre-formed antibodies and serves as a ready-made armor against pathogens that have invaded the body. Plasma/serum therapy has been used against toxins, poisons and venoms, and infectious agents, including, for the first time in any pandemic, the 1918 influenza pandemic, where serum from recovered patients was used to treat acutely ill patients.⁽¹⁾ By the early 20th century, plasma therapy was employed for the treatment of bacterial infections⁽²⁾ and viral diseases such as measles⁽³⁾ and polio.⁽⁴⁾ The discovery of antibody purification through ethanol fractionation of plasma⁽⁵⁾ was later adapted for many polyclonal antibody products.

The diphtheria antitoxin can neutralize the circulating toxin and has been used for clinical treatment since the late

¹Ella Foundation, Hyderabad, India.

²National Institute of Animal Biotechnology, Hyderabad, India.

³Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, France.

⁴Indian Institute of Technology Palakkad, Palakkad, Kerala, India.

⁵Centre National de la Recherche Scientifique (CNRS) Bureau India, IFI, New Delhi, India.

1800s.^(6,7) Similarly, the botulinum antitoxin effectively binds to the free toxin in the blood and prevents the progression of the symptoms, although it cannot reverse the paralysis that has already set in.⁽⁸⁾ Antivenins were first successfully used in humans in 1896.⁽⁹⁾ The antivenins are typically produced against poisons of various animal species, most commonly snakes, spiders, and jellyfish, existing in the pertinent geographic regions, and are either whole IgG molecules or the F(ab')₂ or Fab fragments.

Treatment with antibodies has also been employed against several viruses. The smallpox vaccine was frequently associated with a number of serious adverse events, which had to be managed by administering the vaccinia immune globulin (VIG). The VIG was also used to prevent smallpox among close contacts of patients with the disease.⁽¹⁰⁾ Post-exposure prophylaxis of rabies involves a combination of active immunization and passive Ig therapy. The anti-rabies Ig is typically derived from vaccinated equines or humans, but these are gradually being replaced by monoclonal antibodies (MAbs).^(11,12) Hepatitis B immune globulin (HBIG) is used to provide short-term protection against hepatitis B infection. A combination of hepatitis B vaccine and one dose of HBIG produces immediate and sustained high levels of protective antibody against hepatitis B.⁽¹³⁾ The HBIG is also being explored in the treatment of chronic hepatitis B.⁽¹⁴⁾ Varicella zoster immunoglobulin (VZIG) is administered to reduce the severity of the disease.^(15,16) Virus neutralizing antibodies (NAbs) targeting the epitopes on the varicella-zoster virus (VZV) envelope fusion proteins gH or gH-gL complex, which mediate virus entry, may replace the VZIG for antibody therapy.^(17,18) In the case of human cytomegalovirus (HCMV), identification of potent NAbs against the HCMV gH/gL/pUL128-131 complex^(19,20) has led to the development of therapeutic antibodies to improve transplantation outcomes.⁽²¹⁾ For respiratory syncytial virus (RSV), various polyclonal antibody and MAb formulations are being explored for their therapeutic potential.^(22,23)

Specific plasma therapy received renewed attention in recent times for its use against deadly infectious diseases. One such disease is the middle eastern respiratory syndrome (MERS), caused by MERS coronavirus (MERS-CoV), which has a case fatality rate of 35%. Owing to the small number of donors and insufficient antibody titers in convalescent plasma, establishing homo-specific plasma therapy for MERS has been difficult, and hence, equine and dromedary camel antibodies have been explored as alternatives.^(24,25) Serum from dromedary camels was demonstrated to reduce the severity of the lung pathology and viral load in a mouse model.⁽²⁵⁾ Similarly, purified equine IgG and F(ab')₂ raised against MERS-CoV was demonstrated to neutralize the virus *in vitro*, and it reduced the virus load in a mouse model.⁽²⁴⁾ However, neither has been used for the treatment of humans suffering from MERS. During the Ebola virus disease (EVD) outbreak in 2013–2016, antibody-based treatments were evaluated for their preventive or therapeutic potential. Plasma therapy for EVD was found to be safe, but no significant survival benefit was recorded.⁽²⁶⁾ Polyclonal sera produced in cattle engineered to generate human antibodies (transchromosomal cows) provided 90% protection in a mouse model of lethal EVD,⁽²⁷⁾ and they protected all the treated non-human primates (NHPs) when administered on

the 1st or 3rd day post-challenge.⁽²⁸⁾ In addition, anti-MERS-CoV antibodies produced in transchromosomal cows were found to be safe in Phase I clinical trials.⁽²⁹⁾

A major application of plasma/serum therapy against infectious disease has been during the currently ongoing pandemic of coronavirus disease-2019 (COVID-19), which is caused by severe acute respiratory syndrome CoV-2 (SARS-CoV-2). In the initial phase of the pandemic, this was the only option that was explored. This stemmed from the fact that infusion of convalescent plasma was found to provide a beneficial clinical outcome against SARS,⁽³⁰⁾ which is caused by the related virus, SARS-CoV-1. Several studies, including randomized controlled trials (RCTs) as well as observational studies, showed favorable trends in terms of viral load, oxygen demand, progression to intensive care, recovery time, and/or death.^(31–33) Mechanistically, besides the obvious effect of antibodies, the reversals in disease severity could be attributed to a transient reduction in detrimental cytokines and changes in lymphocyte subpopulations.⁽³⁴⁾ However, plasma therapy could not attain the status of standard care owing to its application based on the clinician's judgment of risk versus benefit to individual patients, lack of sufficient data from RCTs, and uncertainties about its efficacy.

Polyclonal antibodies contained in the plasma/serum target multiple epitopes and are likely to protect even against escape mutants of pathogens. However, the disadvantages of the use of plasma/serum are batch-to-batch inconsistencies,⁽³⁵⁾ low content of specific antibodies,^(36,37) risks of adventitious agents,⁽³⁸⁾ and development of allergic reactions.⁽⁸⁾ In addition, although robust NAb responses are produced against acute viral infections in the majority of individuals, some viruses such as human immunodeficiency virus (HIV),^(39,40) influenza virus,⁽⁴¹⁾ Lassa virus,^(42,43) Ebola virus, and SARS-CoV-2⁽⁴⁴⁾ are known to induce NAb responses at much lower levels, possibly making plasma therapy ineffective for these viral infections. Variation in the structural proteins of viruses such as HIV and influenza virus could also influence the success or failure of antibody therapy. Inconsistent NAb titer in the convalescent plasma was a major drawback that limited its use against COVID-19.

Intravenous Immunoglobulin Therapy

Intravenous immunoglobulin (IVIg) is prepared from normal plasma obtained from thousands of healthy donors. It consists of IgG, IgA, traces of other Ig's, cytokines, and soluble receptors. The IVIg preparations are approved for use in immunotherapy of a variety of diseases. IVIg modulate both innate and adaptive immune systems through several mechanisms such as (1) neutralization of activated complement components^(45–47); (2) inhibition of activation and functions of innate immune cells such as dendritic cells,^(48,49) monocytes, macrophages,^(50–53) neutrophils,⁽⁵⁴⁾ and natural killer (NK) cells^(55,56); (3) modulation of B cell functions^(57,58) and its activation through toll-like receptors,^(59,60) B cell receptors,⁽⁶¹⁾ and interleukin (IL)-4+CD40⁽⁶²⁾; (4) enhancing the differentiation of plasma cells⁽⁶³⁾; and (5) reciprocal regulation of regulatory T cells⁽⁶⁴⁾ and effector T cells such as Th1 and Th17 subsets, and downregulation of the production of inflammatory cytokines.^(65–68)

Apart from their use in immune disorders, IVIg have been used for various human infectious diseases. The beneficial

effects of IVIg have been demonstrated against various bacterial infections such as severe invasive group A streptococcal disease, streptococcal toxic shock syndrome, necrotizing *Staphylococcus aureus* sepsis, recurrent bacterial infections in patients with hypogammaglobulinemia, polyneuropathy associated with *Campylobacter jejuni*, recurrent *Clostridium difficile* colitis, *Chlamydia pneumoniae*, and *Salmonella typhimurium* infections. The IVIg therapy has anti-inflammatory effects and can neutralize bacterial toxins with varying efficacy.⁽⁶⁹⁾ Higher doses of IVIg are recommended as a last resort of treatment for specific conditions such as recurrent *C. difficile* colitis and other bacterial diseases. IVIg were also demonstrated to be beneficial against viral infections and diseases such as West Nile, childhood HIV, parvovirus B19, HCMV-induced pneumonitis after transplantation, genital herpes, enteroviruses, and VZV. Further details about the applications of IVIg in infectious diseases are reviewed elsewhere.^(70,71)

MAbs as Therapeutic Agents

MAB therapy has gained a lot of traction in recent times. MAbs bind to specific epitopes in the target antigen. Initially, the application of MAbs was restricted to the development of diagnostics; therapeutic application was constrained by the immunogenic potential and poor efficacy due to the lack of effector function associated with murine antibodies. The United States Food and Drugs Administration (US FDA) approved the first therapeutic MAb (muromonab-CD3) of murine origin in 1986. Subsequently, modified antibodies consisting of murine variable domain and human constant domain were developed and shown to have lower side-effects without compromising the binding ability and led to the approval of the chimeric MAbs for various indications, namely, cancer, infectious diseases, genetic diseases, allergic conditions, etc. The MAbs were further humanized to contain only the complementary-determining region (CDR) of murine origin in a human antibody backbone, by employing the CDR grafting technique.⁽⁷²⁾ The next-generation antibodies were fully human MAbs generated through phage display,^(73,74) transgenics,^(75,76) and B cell cloning techniques. MAbs produced through phage display have been used to target tumor necrosis factor α (TNF α),⁽⁷⁷⁾ B-lymphocyte stimulator,⁽⁷⁸⁾ vascular endothelial growth factor receptor-2,⁽⁷⁹⁾ epidermal growth factor receptor,⁽⁸⁰⁾ interleukin-23,⁽⁸¹⁾ programmed cell death ligand 1,⁽⁸²⁾ plasma kallikrein,⁽⁸³⁾ interferon γ (IFN γ),⁽⁸⁴⁾ and CD22 conjugated with a toxic fragment of *Pseudomonas* exotoxin A.⁽⁸⁵⁾ The pioneering work on B cell cloning and expansion from human peripheral blood mononuclear cells (PBMCs), followed by immortalization with Epstein-Barr virus^(86,87) or isolation of human PBMC's or plasmablasts and cloning the antibody heavy and light chain genes⁽⁸⁸⁻⁹⁰⁾ has advanced human MAB field rapidly. Numerous human anti-SARS-CoV-2 MAB candidates have been derived from PBMCs and are under various stages of development. Antibodies are also being engineered to be bi-specific, where each arm is specific to a different antigen. There are multiple therapeutic bi-specific antibody candidates under development and these are reviewed elsewhere.⁽⁹¹⁾

MAbs in Cancer Therapeutics

Immunotherapy is an emerging arena for the treatment of cancer,⁽⁹²⁻⁹⁴⁾ and it encompasses vaccines, oncolytic viruses,

immune checkpoint regulators, and adoptive transfer of *ex vivo* activated T and NK cells. In this review, we focus on MAB therapy of cancers. Antibodies can recognize specific targets on tumor cells *via* their Fab domain and engage components of the immune system *via* the Fc region to destroy the tumor cells. The IgG subclass is mostly used in these treatments due to its ability to interact with the Fc γ receptor (Fc γ R) on macrophages and natural killer cells that are crucial for anti-cancer immune functions. The effector mechanisms are due to receptor or ligand blocking, and antibody- or complement-mediated cytotoxicity or phagocytosis. MAbs may either directly attack the tumor cells or can be conjugated to a toxin, drug, or a radioisotope that has antitumor effects.⁽⁹⁵⁾

Another way to treat cancers is to target immune checkpoint mediators, which modulate immune homeostasis and hence are necessary for self-tolerance. Tumor cells manipulate the checkpoint by binding to T cell receptors, thereby switching them "off." The immune checkpoint inhibitors (ICI) prevent inactivation of T cells, thereby allowing them to eliminate the mutant cells.⁽⁹⁶⁾ The targets of ICIs include cytotoxic T-lymphocyte associated protein 4 (CTLA-4), programmed death protein-1 (PD-1) and its ligand programmed death ligand 1 (PDL-1).^(97,98) The inhibitory receptor CTLA-4 prevents T cell activation when bound to the B7 receptor on antigen presenting cells.⁽⁹⁹⁾ Ipilimumab, the MAB against CTLA-4, was the first ICI approved by the US FDA for the treatment of melanoma. However, the use of these antibodies had resulted in immune-related adverse events in 10%–30% of the patients.⁽¹⁰⁰⁾ In case of the PD-1 receptor, its binding to PDL-1 on tumor cells suppresses T cell activation. The anti-PD-1 antibodies, Pembrolizumab and Nivolumab and the anti-PDL-1 antibodies, Atezolizumab, Avelumab, and Duvalumab effectively inhibit the PD-1 and PDL-1 interaction, resulting in activation of T cells. In clinical trials, a combination to Ipilimumab and Nivolumab has shown good clinical outcome in patients with metastatic melanoma.^(101,102) A list of MAbs approved for clinical use is provided in Table 1.

MAbs for Treatment of Viral Diseases

Among the infectious agents, viruses are obligated intracellular pathogens and are not inhibited by antibiotics. Several therapeutic interventions have been devised against viral infections.⁽¹⁰³⁾ In the case of rabies virus, cocktails consisting of two MAbs have been demonstrated to have broader virus neutralizing ability compared with formulations with only one MAB.⁽¹¹⁾ With RSV, Palivizumab, which recognizes an epitope in the fusion protein,^(104,105) was shown to reduce hospitalization by 55% in premature infants and in those with bronchopulmonary dysplasia.⁽¹⁰⁶⁾

Three MAB therapies have been evaluated in clinical trials against EVD. A single MAB, mAb114, which targets the receptor binding domain (RBD) of the Ebola virus glycoprotein (GP), was found to be effective.⁽¹⁰⁷⁾ REGN-EB3, a combination of three MAbs produced in humanized mice,^(108,109) binds to non-overlapping epitopes of GP, neutralizes Ebola virus, and triggers Fc γ RIIIa. Both mAb114⁽¹¹⁰⁾ and REGN-EB3⁽¹¹¹⁾ have been found to be safe, and to significantly reduce the high fatality rate of EVD in humans.⁽¹¹²⁾ ZMapp, another combination of three chimeric MAbs produced in the plant *Nicotiana benthamiana*, was superior by 91.2% when compared with the standard of care alone.⁽¹¹³⁾

TABLE 1. LIST OF UNITED STATES FOOD AND DRUGS ADMINISTRATION APPROVED MONOCLONAL ANTIBODIES FOR IMMUNOTHERAPY OF CANCER

Target	Drug	Clinical use	Ref.
Epidermal growth factor receptor	Necitumumab	Squamous non-small-cell lung cancer	(153)
	Cetuximab	Colorectal, head and neck cancer	(154)
VEGF	Panitumumab	Colorectal cancer	(155)
	Nimotuzumab	Squamous cell carcinoma, glioma	(156)
	Bevacizumab	Anti-angiogenic therapy	(157)
CD19-directed CD3 T cell engager	Blinatumomab	Acute lymphoblastic leukemia	(158)
CD20	Ibritumomab	Diffuse Large B cell Lymphoma	(159)
	Rituximab	Non-Hodgkin's lymphoma	(160)
CD33 (myeloid cell surface antigen on leukemia cells)	Tositumomab	Non-Hodgkin's lymphoma	(161)
	Ofatumumab	Chronic lymphocyte leukemia and multiple sclerosis	(162)
CD38	Obinutuzumab	Chronic lymphocytic leukemia (in combination with chlorambucil)	(163)
CD52	Gemtuzumab	Acute myeloid leukemia	(164)
HER2/neu receptor	Daratumumab	Multiple myeloma	(165)
PD-1	Alemtuzumab	Chronic lymphocytic leukemia	(166)
	Trastuzumab	Breast cancer	(167)
PD-L1	Pembrolizumab	Cervical cancer	(168)
	Nivolumab	Head and neck squamous cell carcinoma	(169)
PD-L1	Avelumab	Renal cell cancer	(170)
	Durvalumab	Hodgkin's lymphoma	(171)
SLAM F7	Atezolizumab	Squamous cell carcinoma of the head and neck	(172)
	Elotuzumab	Merkel cell carcinoma	(173)
GD2	Atezolizumab	Non-small cell lung cancer	(174)
CTLA-4	Atezolizumab	Urothelial cancers	(175)
	Atezolizumab	Unresectable stage III non-small cell lung cancer	(176)
CTLA-4	Atezolizumab	In combination with carboplatin and etoposide for treatment of small cell lung cancer,	(177)
	Atezolizumab	In combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.	(178)
GD2	Dinutuximab	Multiple myeloma (used in combination with lenalidomide and dexamethasone)	(179)
CTLA-4	Dinutuximab	Neuroblastoma in pediatric patients	(180)
	Ipilimumab	Melanoma	(181)

CTLA-4, cytotoxic T-lymphocyte associated protein 4; GD2, disialoganglioside; HER2, human epidermal growth factor receptor 2; PD-1, programmed death protein-1; PDL-1, programmed death ligand 1; SLAM F7, signaling lymphocyte activation molecule 7; VEGF, vascular endothelial growth factor.

Various approaches were followed for the development of neutralizing MAbs against MERS-CoV. These were primarily derived from infected patients,^(114–118) immunized mice,^(119–122) or naive human antibody libraries.^(123–125) Most of these antibodies target the RBD of the MERS-CoV Spike protein and interfere in the virus entry through human dipeptidyl peptidase-4. In a marmoset model of MERS, the MAb combination of REGN3048 and REGN3051 proved efficacious in a prophylactic regimen⁽¹¹⁷⁾ and the Phase I human clinical trial results are not yet published.⁽¹²⁶⁾

MAbs for COVID-19 Therapy

Owing to the close relatedness of SARS-CoV-2 to SARS-CoV-1, initial efforts of MAb therapy against the former focused on repurposing anti-SARS-CoV-1 MAbs with cross-neutralizing activity against SARS-CoV-2.^(127,128) Later, memory B cells specific to the RBD of SARS-CoV-2 S protein were used to generate SARS-CoV-2-specific IgG1 MAbs.⁽¹²⁹⁾ These antibodies block the interaction between SARS-CoV-2 and its receptor, angiotensin converting enzyme-2 (ACE2).

Since then, several MAbs have been used in therapeutic intervention of COVID-19. Most of them target the RBD and interfere with the RBD-ACE2 interaction, preventing the entry of SARS-CoV-2 into cells.^(130–135) The list of MAbs that are currently in various phases of clinical trial is provided in Table 2. In addition, antibodies binding to the N-terminal domain of S protein^(136,137) or a distinct proteoglycan epitope⁽¹³⁸⁾ have been demonstrated to neutralize SARS-CoV-2, and these could be developed for therapeutic purposes.

Therapeutic antibody preparations for COVID-19 with single NAb could be ineffective over time due to the emergence of escape mutants, as demonstrated, for instance, with hepatitis B virus⁽¹³⁹⁾ or RSV,⁽¹⁰⁴⁾ or it can have a broader neutralizing ability as shown with rabies virus⁽¹¹⁾ or SARS-CoV-2.⁽¹³⁸⁾ The emergence of SARS-CoV-2 variants such as the UK variant (SARS-CoV-2 VOC 202012/01) and the South African variant (SARS-CoV-2 501Y.V2) with the potential to escape single MAb therapy has led to the viewpoint that combinatorial MAb therapy is better for effective treatment.⁽¹⁴⁰⁾

A cocktail of REGN10933 and REGN10987, which target non-overlapping epitopes on the SARS-CoV-2 spike protein,

TABLE 2. MONOCLONAL ANTIBODIES AGAINST SYNDROME CoV-2 S PROTEIN THAT ARE IN CLINICAL TRIALS^a

Product name	Status	Developer
REGN-COV2 (REGN10933/Casirivimab +REGN10987/Imdevimab)	Phase 3	Regeneron/NIAID
Bamlanivimab (LY3819253, LY-CoV555)	Phase 3	AbCellera/Eli Lilly/NIH
Sotrovimab (VIR-7831/GSK4182136)	Phase 3	Vir biotechnology/GSK
AZD7442 (AZD8895/Tixagevimab +AZD1061/Cilgavimab)	Phase 3	AstraZeneca/Vanderbilt University Medical Center/DARPA/BARDA
Regdanvimab (CT-P59)	Phase 3	Celltrion
DXP-593	Phase 2	Beigene/Singlomics Biopharmaceuticals/Peking University
Etesevimab (JS016, LY-CoV016, LY3832479)	Phase 2	Junshi Biosciences/Institute of Microbiology, Chinese Academy of Sciences/Eli Lilly
DZIF-10c	Phase 2	University of Cologne/The German Center for Infection Research/BoehringerIngelheim
COVI-AMG (STI-2020)	Phase 2	Sorrento Therapeutics
STI-1499/COVI-SHIELD	Phase 1	Sorrento/Mount Sinai Health System
TY027	Phase 1	Tychan
BRII-196	Phase 1	Brii Bio/TSB Therapeutics/Tsinghua University
BRII-198	Phase 1	Brii Bio/TSB Therapeutics/Tsinghua University
SCTA01	Phase 1	Sinocelltech Ltd/Chinese Academy of Sciences
MW33	Phase 1	Mabwell (Shanghai) Bioscience Co., Ltd.
HFB30132A	Phase 1	HiFiBiO Therapeutics
HLX70	Phase 1	Hengenix Biotech, Inc.
ADM03820	Phase 1	Ology Bioservices

^aTable modified from COVID-19 Therapeutic Antibody Tracker to include the products that are in clinical trial (<https://chineseantibody.org/covid-19-track>)⁽¹⁰⁹⁾

BARDA, Biomedical Advanced Research and Development Authority, USA; DARPA, Defense Advanced Research Projects Agency, USA; GSK, GlaxoSmithKline; NIAID, National Institute of Allergy and Infectious Diseases, USA; NIH, National Institutes of Health, USA.

is in Phase 3 clinical trials. This combination has been shown to markedly reduce respiratory viral load in an NHP model, even when the animals were challenged with a 10-fold higher virus load.⁽¹⁴¹⁾ In Phase 1–3 clinical trials, where non-hospitalized COVID-19 positive patients were enrolled, this cocktail was able to reduce the viral load by two logs as compared with subjects who received the placebo.⁽¹⁴²⁾

Another example of a cocktail is AZD7442, a combination of AZD8895/Tixagevimab and AZD1061/Cilgavimab, which recognizes non-overlapping epitopes on the RBD and functions in synergy.^(143,144) These antibodies are optimized with half-life extension and reduced Fc receptor binding and, hence, called long-acting antibodies. Based on the earlier studies,^(145–147) the half-life extension is expected to protect from COVID-19 for 6–12 months and the modification in the Fc region reduces the risk of antibody dependent enhancement (ADE) of the disease. This AZD7442 cocktail demonstrated prophylactic and therapeutic efficacy in mice transiently expressing ACE2 as well as in immunocompetent mice. Sotrovimab (VIR-7831) is a human MAb that was isolated from SARS-CoV-1 convalescent memory B cells. It recognizes a proteoglycan motif, and its neutralization effect is due to steric interference rather than competing with receptor attachment.⁽¹³⁸⁾ It is currently being evaluated in Phase III clinical trials (NCT04545060).

Regdanvimab (CT-P59) is a human MAb that potently neutralizes SARS-CoV-2 isolates, including the D614G variant without the ADE effect. Structural studies show that Regdanvimab binds to the receptor-binding motif within SARS-CoV-2 RBD. CT-P59 was initially shown to be effective against SARS-CoV-2 in preclinical studies in ferrets, hamsters, and rhesus monkeys.⁽¹⁴⁸⁾ Preliminary efficacy data

indicate that CT-P59 significantly reduces by >50% the proportion of patients requiring hospitalization or oxygen therapy, as compared with the placebo group.⁽¹⁴⁹⁾

Another potential therapeutic NAb candidate named LY-CoV555 (Bamlanivimab) is not modified in the Fc region. The NHP challenge studies indicated that LY-CoV555 was effective in reducing the virus replication in the upper and the lower respiratory tract.⁽¹⁵⁰⁾ In Phase II clinical trials, a majority of the subjects showed viral clearance by day 11.⁽¹⁵¹⁾ In a randomized Phase II/III trial, however, Bamlanivimab monotherapy failed to significantly reduce viral load, but the combination therapy of Bamlanivimab and Etesevimab significantly reduced SARS-CoV-2 viral load at day 11.⁽¹⁵²⁾ The clinical trial outcomes of other neutralizing MAb are yet to be published.

Another area of immunotherapy for COVID-19 has been to dampen the hyper-immune response, which appears to be directly correlated with the severity of disease. Increased concentrations of granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF), IFN γ , IL-1 β , IL-2, IL-6, IL-7, IL-8, IL-9, IL-17, C-X-C motif chemokine 10 (CXCL10), chemokine ligand 2 (CCL2), CCL3, and CCL4 have been observed in severely affected patients. Therefore, several of these cytokines and chemokines have been targeted for mitigating the inflammatory response, and they include IL-6 receptor (IL-6R), IL-6, GM-CSF, and IL-1 β . A summary of the status of these therapeutics is provided in Table 3.

Perspective

Antibody therapy has become pivotal against cancers and emerging pathogens, especially those pathogens that cause

TABLE 3. MONOCLONAL ANTIBODIES TARGETING THE HOST PROTEINS TO TREAT COVID-19^a

<i>Product name</i>	<i>Target</i>	<i>Status</i>	<i>Developer</i>
Itolizumab (EQ001, H-T1, T1-h)	CD6	Approved	Biocon
Levilimab (BCD-089)	IL-6R	Approved	Biocad
Tocilizumab	IL-6R	Phase 4	Hoffmann-La Roche/multiple sponsors
Ravulizumab-cwvz	C5	Phase 4	Alexion Pharmaceuticals/Cambridge University Hospitals NHS Foundation Trust
Sarilumab (SAR153191, Kevzara)	IL-6R	Phase 4	Regeneron/Sanofi/multiple sponsors
Siltuximab	IL-6	Phase 3	University Hospital, Ghent/A.O. Ospedale Papa Giovanni XXIII
Lenzilumab	GM-CSF	Phase 3	Humanigen
Canakinumab	IL-1 β	Phase 3	Novartis
CD24Fc (SACCOVID)	DAMPs, Siglec G/10	Phase 3	OncoImmune
Olokizumab	IL-6	Phase 3	R-Pharm JSC/Cromos Pharma
Leronlimab (PRO-140)	CCR5	Phase 3	CytoDyn
Emapalumab (Gamifant)	IFN γ	Phase 3	Swedish Orphan Biovitrum
Bevacizumab	VEGF	Phase 3	Qilu Hospital of Shandong University/Renmin Hospital of Wuhan University/IalyMoriggiaPelasciniGravedona Hospital S.p.A/Wuhan University/Jiangbei Union Hospital of Huazhong University of science and technology/Shandong Provincial Chest Hospital
IFX-1 (BDB-001)	C5a	Phase 3	Staidson/InflaRx/Beijing Defengrei Biotechnology
Clazakizumab	IL-6	Phase 3	Medical University of Vienna/NYU Langone Health
RPH-104	IL-1	Phase 3	R-Pharm JSC, Cromos Pharma
Pamrevlumab (FG-3019)	Connective tissue growth factor (CCN2)	Phase 3	FibroGen, Inc.
Mavrilimumab	GM-CSF receptor	Phase 3	Kiniksa Pharmaceuticals/multiple sponsors
UTTR1147A	IL-22R	Phase 2	Genentech
F-652	IL-22R	Phase 2	Generon (Shanghai) Corporation Ltd.
APG101	CD95 ligand	Phase 2	Apogenix GmbH
Crizanlizumab	P-selectin	Phase 2	Johns Hopkins University/Novartis/Socar Research SA/Brigham and Women's Hospital
Garadacimab (CSL312)	Factor XIIIa	Phase 2	CSL Behring
Infliximab	TNF	Phase 2	Tufts Medical Center/NIH
APN01	SARS-CoV-2 S protein	Phase 2	APEIRON Biologics
Otilimab	GM-CSF	Phase 2	GSK
Avdoralimab	C5aR	Phase 2	Innate Pharma SA
Zansecimab (LY3127804)	Ang-2	Phase 2	Eli Lilly
Eculizumab	C5	Phase 2	Alexion Pharmaceuticals/Hudson Medical
Camrelizumab	PD-1	Phase 2	Jiangsu HengRuiMedicine/Southeast University/Wuhan JinyintanHospital
Pembrolizumab	PD-1	Phase 2	MedicaScientia Innovation Research (MEDSIR)
Gimsilumab	GM-CSF	Phase 2	Roivant Sciences
Ixekizumab	IL-17A	Phase 2	Xiangya Hospital of Central South University
BMS-986253, HuMax-IL8, HuMax-Inflam/MDX018	IL-8	Phase 2	Bristol-Myers Squibb
Astegolimab	IL-33R	Phase 2	Genentech
Secukinumab (AIN457)	IL-17A	Phase 2	Lomonosov Moscow State University Medical Research and Educational Center
ATYR1923	Neuropilin-2	Phase 2	aTyr Pharma, Inc.
Axatilimab (SNDX-6352)	CSF-1R	Phase 2	Syndax Pharmaceuticals, Inc.
NN8765, IPH-2201, NNC141-0100	NKG2A (CD159a)	Phase 2	Innate Pharma SA
CNTO 136	IL-6	Phase 2	Janssen
CERC-002	LIGHT	Phase 2	Cerecor
TJM2 (TJ003234)	GM-CSF	Phase 2	I-Mab Biopharma
IC14	CD14	Phase 2	Implicit Bioscience
Meplazumab	CD147	Phase 2	Tang-Du Hospital
Adrecizumab (HAM8101)	Adrenomedulin	Phase 1	Adrenomed AG
CPI-006	CD73	Phase 1	Corvus Pharmaceuticals
hzVSFv13	Vimentin	Phase 1	ImmuneMed
Lanadelumab	Kallikrein	Phase 1	Radboud University/Takeda
AK119	CD73	Phase 1	Akesobio
Daxdilimab (VBI7734)	ILT7	Phase 1	Viela Bio
Efineptakinalfa (GX-17)	IL-7R	Phase 1	NeoImmuneTech

^aTable modified from COVID-19 Therapeutic Antibody Tracker to include the products that are in clinical trial (<https://chineseantibody.org/covid-19-track>).⁽¹⁰⁹⁾

CCR5, C-C chemokine receptor 5; DAMP, danger-associated molecular pattern; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte-macrophage CSF; IFN γ , interferon γ ; IL, interleukin; IL-6R, IL-6 receptor; LIGHT, homologous to lymphotoxin, exhibits inducible expression and competes with herpes simplex virus glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytes; NHS, National Health Service, UK; SARS-CoV-2, syndrome CoV-2; TNF, tumor necrosis factor.

acute hemorrhagic fever or hyper-inflammatory conditions such as a cytokine storm. Both polyclonal (plasma/serum) and MAb therapy have distinct advantages and disadvantages. Plasma/serum is very likely to contain multi-specific antibodies that can function through their binding of more than one region in an antigen or more than one antigen on a pathogen. Any inter-host variation in antigenic determinants of the pathogen is likely to be circumvented by polyclonal antibodies. However, standardization in terms of quantifiable levels, affinity and avidity, potency (e.g., neutralization levels), as well as freedom from adventitious agents are an issue with plasma/serum therapy, besides hypersensitivity reactions related to the use of sera from heterologous species as well as transfusion-related histo-incompatibility reactions related to heterologous individuals are a deterrent for the use of convalescent or immune plasma/sera. Additional challenges include acquiring patients, adequate availability of plasma, and harvesting at an appropriate time. On the other hand, MAbs provide high specificity, consistent affinity and avidity, and antigen specificity, besides being amenable to reliable quality control during the production process. However, single MAb therapy could be ineffective in cases where the pathogen frequently mutates, or could even drive the emergence of variant strains. Hence, recent research has focused on deriving MAbs reactive to conserved epitopes or to use a combination of two or more MAbs together. However, clinical use of MAb has been skewed toward treating cancer or toward treating inflammatory conditions, whereas only a handful of products are licensed for use against infectious diseases. However, together with the adoption of standardized procedures for the production of therapeutic antibodies, and the collaborative efforts driven by the COVID-19 pandemic, MAb therapy has likely become a benchmark for the intervention of any future infectious disease outbreaks.

Author Disclosure Statement

The work was conceived and structured by S.V.K, N.R.H., and J.B. Acquisition of the literature and the writing was done by D.K., S.G., and N.R.H.; N.R.H., J.B., and S.V.K. critically reviewed and revised the article. All the authors declare that there are no competing interests.

Funding Information

J.B. and S.V.K. acknowledge the support of CSL Behring, France. J.B. also acknowledges the support of Agence Nationale de la Recherche, France under the call "Flash COVID-19" (ANR-20-COVI-0093-COVIMUNE).

References

1. Luke TC, Kilbane EM, Jackson JL, and Hoffman SL: Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? *Ann Intern Med* 2006;145:599–609.
2. Casadevall A, and Scharff MD: Serum therapy revisited: Animal models of infection and development of passive antibody therapy. *Antimicrob Agents Chemother* 1994;38:1695–1702.
3. Janeway CA: Use of concentrated human serum gamma-globulin in the prevention and attenuation of measles. *Bull N Y Acad Med* 1945;21:202–222.

4. Hammon WM, Coriell LL, Wehrle PF, and Stokes J, Jr.: Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses. *J Am Med Assoc* 1953;151:1272–1285.
5. Kendrick DB: Blood Program in World War II. Office of the Surgeon General, Dept. of the Army: For sale by the Supt. of Docs., U.S. G.P.O, Washington, DC, 1964.
6. MacGregor RR: *Corynebacterium Diphtheriae* (Diphtheria), 8th ed. Elsevier, Philadelphia, PA, USA, 2015.
7. Acosta PLM, Susan Hariri, and Tejpratap SP: Tiwari: Diphtheria. In: *Epidemiology and Prevention of Vaccine-Preventable Diseases*, Jennifer Hamborsky AK, Charles (Skip) Wolfe (eds.). Centers for Disease Control and Prevention, Atlanta, GA, USA, 2020, pp. 107–118.
8. Schussler E, Sobel J, Hsu J, Yu P, Meaney-Delman D, Grammer LC, 3rd, and Nowak-Wegrzyn A: Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to Botulinum Antitoxin: A Systematic Review. *Clin Infect Dis* 2017;66:S65–S72.
9. Calmette A: On snake venom and the use of antivenom in the therapy of bites poisonous in humans and animals [in French]. *Ann l'Inst Pasteur* 1897;XII:214–237.
10. Wittek R: Vaccinia immune globulin: Current policies, preparedness, and product safety and efficacy. *Int J Infect Dis* 2006;10:193–201.
11. Ding L, Wu M, Zhang H, Zhu X, Hu Y, Li X, Liu J, Tsao E, Liu M, and Li C: Safety, pharmacokinetics and pharmacodynamics of SYN023 alone or in combination with a rabies vaccine: An open, parallel, single dose, phase 1 bridging study in healthy Chinese subjects. *Antiviral Res* 2020;184:104956.
12. WHO: Rabies Monoclonal Antibodies Post Exposure Prophylaxis. World Health Organization, Geneva, Switzerland, 2016.
13. Szmunn W, Stevens CE, Oleszko WR, and Goodman A: Passive-active immunisation against hepatitis B: Immunogenicity studies in adult Americans. *Lancet* 1981;1:575–577.
14. NIH: Hepatitis B Immune Globulin (HBIG) to Restore Immune Control in People with Chronic Hepatitis B, 2018, <https://clinicaltrials.gov/ct2/show/NCT03575208>.
15. CPS: Varicella zoster immune globulin use in neonates and infants. *Can J Infect Dis* 1996;7:17–18.
16. Zaia JA, Levin MJ, Preblud SR, Leszczynski J, Wright GG, Ellis RJ, Curtis AC, Valerio MA, and LeGore J: Evaluation of varicella-zoster immune globulin: Protection of immunosuppressed children after household exposure to varicella. *J Infect Dis* 1983;147:737–743.
17. Birlea M, Owens GP, Eshleman EM, Ritchie A, Traktinskiy I, Bos N, Seitz S, Azarkh Y, Mahalingam R, Gilden D, and Cohrs RJ: Human anti-varicella-zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH/gL complex and neutralizes VZV infection. *J Virol* 2013;87:415–421.
18. Rodriguez JE, Moninger T, and Grose C: Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody. *Virology* 1993;196:840–844.

19. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, Gerna G, Sallusto F, and Lanzavecchia A: Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. *J Virol* 2010;84:1005–1013.
20. Ha S, Li F, Troutman MC, Freed DC, Tang A, Loughney JW, Wang D, Wang IM, Vlasak J, Nickle DC, Rustandi RR, Hamm M, DePhillips PA, Zhang N, McLellan JS, Zhu H, Adler SP, McVoy MA, An Z, and Fu TM: Neutralization of diverse human cytomegalovirus strains conferred by antibodies targeting viral gH/gL/pUL128-131 pentameric complex. *J Virol* 2017;91:e02033-16.
21. Maertens J, Logan AC, Jang J, Long G, Tang JL, Hwang WYK, Koh LP, Chemaly R, Gerbitz A, Winkler J, Yeh SP, Hiemenz J, Christoph S, Lee DG, Wang PN, Holler E, Mielke S, Akard L, Yeo A, Ramachandra S, Smith K, Pertel P, and Segal F: Phase 2 study of anti-human cytomegalovirus monoclonal antibodies for prophylaxis in hematopoietic cell transplantation. *Antimicrob Agents Chemother* 2020;64:e02467-19.
22. Soto JA, Galvez NMS, Pacheco GA, Bueno SM, and Kalergis AM: Antibody development for preventing the human respiratory syncytial virus pathology. *Mol Med* 2020;26:35.
23. Mejias A, Garcia-Maurino C, Rodriguez-Fernandez R, Peeples ME, and Ramilo O: Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. *Vaccine* 2017;35:496–502.
24. Zhao Y, Wang C, Qiu B, Li C, Wang H, Jin H, Gai W, Zheng X, Wang T, Sun W, Yan F, Gao Y, Wang Q, Yan J, Chen L, Perlman S, Zhong N, Zhao J, Yang S, and Xia X: Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model. *Antiviral Res* 2017;137:125–130.
25. Zhao J, Perera RA, Kayali G, Meyerholz D, Perlman S, and Peiris M: Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection. *J Virol* 2015;89:6117–6120.
26. van Griensven J, Edwards T, de Lamballerie X, Semples MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Franssen K, Buyze J, Ravinetto R, Tiberghien P, Claeys Y, De Crop M, Lynen L, Bah EI, Smith PG, Delamou A, De Wegheleire A, and Haba N: Evaluation of convalescent plasma for Ebola virus disease in guinea. *N Engl J Med* 2016;374:33–42.
27. Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coyle EM, Ortiz RA, Fuentes S, Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC, Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, and Jiao JA: Production of potent fully human polyclonal antibodies against Ebola zaire virus in transchromosomal cattle. *Sci Rep* 2016;6:24897.
28. Luke T, Bennett RS, Gerhardt DM, Burdette T, Postnikova E, Mazur S, Honko AN, Oberlander N, Byrum R, Ragland D, St Claire M, Janosko KB, Smith G, Glenn G, Hooper J, Dye J, Pal S, Bishop-Lilly KA, Hamilton T, Frey K, Bollinger L, Wada J, Wu H, Jiao JA, Olinger GG, Gunn B, Alter G, Khurana S, Hensley LE, Sullivan E, and Jahrling PB: Fully human immunoglobulin G from transchromosomal bovines treats nonhuman primates infected with Ebola virus makona isolate. *J Infect Dis* 2018; 218:S636–S648.
29. Beigel JH, Voell J, Kumar P, Raviprakash K, Wu H, Jiao JA, Sullivan E, Luke T, and Davey RT, Jr.: Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomal cattle: A phase 1 randomised, double-blind, single-dose-escalation study. *Lancet Infect Dis* 2018;18:410–418.
30. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, and Cheng G: Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis* 2005;24:44–46.
31. Casadevall A, Grossman BJ, Henderson JP, Joyner MJ, Shoham S, Pirofski LA, and Paneth N: The assessment of convalescent plasma efficacy against COVID-19. *Med (NY)* 2020;1:66–77.
32. Devarasetti PK, Rajasekhar L, Baisya R, Sreejitha KS, and Vardhan YK: A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy. *Immunol Res* 2021;69:18–25.
33. Khadka S, Nisar S, Syed NI, Shrestha DB, and Budhathoki P: Different aspects of convalescent plasma therapy for COVID-19 treatment; a critical review. *Immunopharmacol Immunotoxicol* 2021;43:30–36.
34. Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodriguez Y, Gallo JE, Salazar-Urbe JC, Santander MJ, Cala MP, Zapata W, Zapata MI, Manrique R, Pardo-Oviedo JM, Camacho B, Ramirez-Santana C, Anaya JM, and group C-C-: COVID-19 convalescent plasma composition and immunological effects in severe patients. *J Autoimmun* 2021;118:102598.
35. Felton LD: The units of protective antibody in anti-pneumococcus serum and antibody solution. *J Infect Dis* 1928;43:531–542.
36. Weisman LE, Cruess DF, and Fischer GW: Opsonic activity of commercially available standard intravenous immunoglobulin preparations. *Pediatr Infect Dis J* 1994; 13:1122–1125.
37. Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, Al-Dawood A, Al-Qahtani S, Al-Omari A, Al-Hameed F, Hayden FG, Fowler R, Bouchama A, Shindo N, Al-Khairy K, Carson G, Taha Y, Sadat M, and Alahmadi M: Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. *Emerg Infect Dis* 2016;22:1554–1561.
38. Slade HB: Human immunoglobulins for intravenous use and hepatitis C viral transmission. *Clin Diagn Lab Immunol* 1994;1:613–619.
39. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, and Stamatatos L: Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. *J Virol* 2009;83: 757–769.
40. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, Abdool Karim SS, and Morris L: The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. *J Virol* 2011;85: 4828–4840.
41. Andrews SF, Huang Y, Kaur K, Popova LI, Ho IY, Pauli NT, Henry Dunand CJ, Taylor WM, Lim S, Huang M, Qu

- X, Lee JH, Salgado-Ferrer M, Krammer F, Palese P, Wrammert J, Ahmed R, and Wilson PC: Immune history profoundly affects broadly protective B cell responses to influenza. *Sci Transl Med* 2015;7:316ra192.
42. Sommerstein R, Flatz L, Remy MM, Malinge P, Magistrelli G, Fischer N, Sahin M, Bergthaler A, Igonet S, Ter Meulen J, Rigo D, Meda P, Rabah N, Coutard B, Bowden TA, Lambert PH, Siegrist CA, and Pinschewer DD: Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection. *PLoS Pathog* 2015;11:e1005276.
 43. Jahrling PB, Frame JD, Rhoderick JB, and Monson MH: Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. *Trans R Soc Trop Med Hyg* 1985;79:380–384.
 44. Bosnjak B, Stein SC, Willenzon S, Cordes AK, Puppe W, Bernhardt G, Ravens I, Ritter C, Schultze-Florey CR, Godecke N, Martens J, Kleine-Weber H, Hoffmann M, Cossmann A, Yilmaz M, Pink I, Hoepfer MM, Behrens GMN, Pohlmann S, Blasczyk R, Schulz TF, and Forster R: Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. *Cell Mol Immunol* 2020, DOI: 10.1038/s41423-020-00573-9.
 45. Basta M, and Dalakas MC: High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. *J Clin Invest* 1994;94:1729–1735.
 46. Lutz HU, Stammler P, Bianchi V, Trueb RM, Hunziker T, Burger R, Jelezarova E, and Spath PJ: Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. *Blood* 2004;103:465–472.
 47. Widiapradja A, Vegh V, Lok KZ, Manzanero S, Thundiyil J, Gelderblom M, Cheng YL, Pavlovski D, Tang SC, Jo DG, Magnus T, Chan SL, Sobey CG, Reutens D, Basta M, Mattson MP, and Arumugam TV: Intravenous immunoglobulin protects neurons against amyloid beta-peptide toxicity and ischemic stroke by attenuating multiple cell death pathways. *J Neurochem* 2012;122:321–332.
 48. Bayry J, Bansal K, Kazatchkine MD, and Kaveri SV: DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. *Proc Natl Acad Sci U S A* 2009;106:E24; author reply E25.
 49. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, Chevailler A, Mouthon L, Weill B, Bruneval P, Kazatchkine MD, and Kaveri SV: Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. *Blood* 2003;101:758–765.
 50. Ruiz de Souza V, Carreno MP, Kaveri SV, Ledur A, Sadeghi H, Cavaillon JM, Kazatchkine MD, and Haeffner-Cavaillon N: Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). *Eur J Immunol* 1995;25:1267–1273.
 51. Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, Nutt SL, Hu X, and Ivashkiv LB: FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. *Immunity* 2007;26:67–78.
 52. Kozicky LK, Zhao ZY, Menzies SC, Fidanza M, Reid GS, Wilhelmsen K, Hellman J, Hotte N, Madsen KL, and Sly LM: Intravenous immunoglobulin skews macrophages to an anti-inflammatory, IL-10-producing activation state. *J Leukoc Biol* 2015;98:983–994.
 53. Galeotti C, Hegde P, Das M, Stephen-Victor E, Canale F, Munoz M, Sharma VK, Dimitrov JD, Kaveri SV, and Bayry J: Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin. *Sci Rep* 2016;6:19592.
 54. Casulli S, Topcu S, Fattoum L, von Gunten S, Simon HU, Teillaud JL, Bayry J, Kaveri SV, and Elbim C: A differential concentration-dependent effect of IVIg on neutrophil functions: Relevance for anti-microbial and anti-inflammatory mechanisms. *PLoS One* 2011;6:e26469.
 55. Ruiz JE, Kwak JY, Baum L, Gilman-Sachs A, Beaman KD, Kim YB, and Beer AE: Intravenous immunoglobulin inhibits natural killer cell activity *in vivo* in women with recurrent spontaneous abortion. *Am J Reprod Immunol* 1996;35:370–375.
 56. Finberg RW, Newburger JW, Mikati MA, Heller AH, and Burns JC: Effect of high doses of intravenously administered immune globulin on natural killer cell activity in peripheral blood. *J Pediatr* 1992;120:376–380.
 57. Paquin Proulx D, Aubin E, Lemieux R, and Bazin R: Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). *Clin Immunol* 2010;135:422–429.
 58. Seite JF, Goutsmedt C, Youinou P, Pers JO, and Hillion S: Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells. *J Allergy Clin Immunol* 2014;133:181–188.e181–e189.
 59. Seite JF, Guerrier T, Cornec D, Jamin C, Youinou P, and Hillion S: TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase. *J Autoimmun* 2011;37:190–197.
 60. Kessel A, Peri R, Haj T, Snir A, Slobodin G, Sabo E, Rosner I, Shoenfeld Y, and Toubi E: IVIg attenuates TLR-9 activation in B cells from SLE patients. *J Clin Immunol* 2011;31:30–38.
 61. Seite JF, Cornec D, Renaudineau Y, Youinou P, Mageed RA, and Hillion S: IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. *Blood* 2010;116:1698–1704.
 62. Zhuang Q, Bisotto S, Fixman ED, and Mazer B: Suppression of IL-4- and CD40-induced B-lymphocyte activation by intravenous immunoglobulin is not mediated through the inhibitory IgG receptor FcgammaRIIb. *J Allergy Clin Immunol* 2002;110:480–483.
 63. de Grandmont MJ, Racine C, Roy A, Lemieux R, and Neron S: Intravenous immunoglobulins induce the *in vitro* differentiation of human B lymphocytes and the secretion of IgG. *Blood* 2003;101:3065–3073.
 64. Bayry J, Mouthon L, and Kaveri SV: Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease. *J Rheumatol* 2012;39:450–451.
 65. Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri SV, and Bayry J: Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. *J Allergy Clin Immunol* 2011;127:823–830.e821–e827.
 66. Maddur MS, Kaveri SV, and Bayry J: Comparison of different IVIg preparations on IL-17 production by human Th17 cells. *Autoimmun Rev* 2011;10:809–810.
 67. Maddur MS, Rabin M, Hegde P, Bolgert F, Guy M, Vallat JM, Magy L, Bayry J, and Kaveri SV: Intravenous

- immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barre syndrome patients. *Immunol Res* 2014;60:320–329.
68. Saha C, Das M, Patil V, Stephen-Victor E, Sharma M, Wymann S, Jordi M, Vonarburg C, Kaveri SV, and Bayry J: Monomeric immunoglobulin A from plasma inhibits human Th17 responses *in vitro* independent of Fc α RI and DC-SIGN. *Front Immunol* 2017;8:275.
 69. Schrage B, Duan G, Yang LP, Fraser JD, and Proft T: Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: Implications for treatment of streptococcal toxic shock syndrome. *Clin Infect Dis* 2006;43:743–746.
 70. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, and Kaveri SV: Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era? *Trends Pharmacol Sci* 2004;25:306–310.
 71. Bulletin: I.V. immunoglobulin therapy for infectious diseases. *Drug Ther Bull* 2010;48:57–60.
 72. Jones PT, Dear PH, Foote J, Neuberger MS, and Winter G: Replacing the complementarity-determining regions in a human antibody with those from a mouse. *Nature* 1986;321:522–525.
 73. Smith GP: Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. *Science* 1985;228:1315–1317.
 74. McCafferty J, Griffiths AD, Winter G, and Chiswell DJ: Phage antibodies: Filamentous phage displaying antibody variable domains. *Nature* 1990;348:552–554.
 75. Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, Kuo CC, Mashayekh R, Wymore K, McCabe JG, Munoz-O'Regan D, O'Donnell SL, Lapachet ESG, Bengoechea T, Fishwild DM, Carmack CE, Kay RM, and Huszar D: Antigen-specific human antibodies from mice comprising four distinct genetic modifications. *Nature* 1994;368:856–859.
 76. Mendez MJ, Green LL, Corvalan JR, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL, Luna J, Roy CM, Abderrahim H, Kirschenbaum F, Noguchi M, Smith DH, Fukushima A, Hales JF, Klapholz S, Finer MH, Davis CG, Zsebo KM, and Jakobovits A: Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. *Nat Genet* 1997;15:146–156.
 77. Kempeni J: Preliminary results of early clinical trials with the fully human anti-TNF α monoclonal antibody D2E7. *Ann Rheum Dis* 1999;58(Suppl. 1):I70–I72.
 78. Stohl W, and Hilbert DM: The discovery and development of belimumab: The anti-BLyS-lupus connection. *Nat Biotechnol* 2012;30:69–77.
 79. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, and Eckhardt SG: Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. *J Clin Oncol* 2010;28:780–787.
 80. Dienstmann R, and Tabernero J: Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. *Curr Opin Investig Drugs* 2010;11:1434–1441.
 81. Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak SJ, Jr., Wasfi Y, Wang Y, Szapary P, and Krueger JG: Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. *J Allergy Clin Immunol* 2014;133:1032–1040.
 82. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbe C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, and Nghiem P: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. *Lancet Oncol* 2016;17:1374–1385.
 83. Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, Busse PJ, Anderson J, Magerl M, Martinez-Saguer I, Davis-Lorton M, Zanichelli A, Li HH, Craig T, Jacobs J, Johnston DT, Shapiro R, Yang WH, Lumry WR, Manning ME, Schwartz LB, Shennak M, Soteres D, Zaragoza-Urdaz RH, Gierer S, Smith AM, Tachdjian R, Wedner HJ, Hebert J, Rehman SM, Staubach P, Schranz J, Baptista J, Nothaft W, and Maurer M: Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: A randomized clinical trial. *JAMA* 2018;320:2108–2121.
 84. Cheloff AZ, and Al-Samkari H: Emapalumab for the treatment of hemophagocytic lymphohistiocytosis. *Drugs Today (Barc)* 2020;56:439–446.
 85. Janus A, and Robak T: Moxetumomab pasudotox for the treatment of hairy cell leukemia. *Expert Opin Biol Ther* 2019;19:501–508.
 86. Aman P, Ehlin-Henriksson B, and Klein G: Epstein-Barr virus susceptibility of normal human B lymphocyte populations. *J Exp Med* 1984;159:208–220.
 87. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, and Lanzavecchia A: An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. *Nat Med* 2004;10:871–875.
 88. Smith K, Garman L, Wrarmert J, Zheng NY, Capra JD, Ahmed R, and Wilson PC: Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. *Nat Protoc* 2009;4:372–384.
 89. Obiakor H, Sehgal D, Dasso JF, Bonner RF, Malekafzali A, and Mage RG: A comparison of hydraulic and laser capture microdissection methods for collection of single B cells, PCR, and sequencing of antibody VDJ. *Anal Biochem* 2002;306:55–62.
 90. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, and Wardemann H: Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. *J Immunol Methods* 2008;329:112–124.
 91. Labrijn AF, Janmaat ML, Reichert JM, and Parren P: Bispecific antibodies: A mechanistic review of the pipeline. *Nat Rev Drug Discov* 2019;18:585–608.
 92. Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papeja N, and Miller WH, Jr.: A review of cancer immunotherapy: From the past, to the present, to the future. *Curr Oncol* 2020;27:S87–S97.
 93. Wahid B, Ali A, Rafique S, Waqar M, Wasim M, Wahid K, and Idrees M: An overview of cancer immunotherapeutic strategies. *Immunotherapy* 2018;10:999–1010.
 94. Waldman AD, Fritz JM, and Lenardo MJ: A guide to cancer immunotherapy: From T cell basic science to clinical practice. *Nat Rev Immunol* 2020;20:651–668.

95. Coulson A, Levy A, and Gossell-Williams M: Monoclonal antibodies in cancer therapy: Mechanisms, successes and limitations. *West Indian Med J* 2014;63:650–654.
96. Park R, Winnicki M, Liu E, and Chu WM: Immune checkpoints and cancer in the immunogenomics era. *Brief Funct Genomics* 2019;18:133–139.
97. Hargadon KM, Johnson CE, and Williams CJ: Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. *Int Immunopharmacol* 2018;62:29–39.
98. He X, and Xu C: Immune checkpoint signaling and cancer immunotherapy. *Cell Res* 2020;30:660–669.
99. Leach DR, Krummel MF, and Allison JP: Enhancement of antitumor immunity by CTLA-4 blockade. *Science* 1996; 271:1734–1736.
100. Das S, and Johnson DB: Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. *J Immunother Cancer* 2019;7:306.
101. Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, and Wolchok JD: Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. *Lancet Oncol* 2018;19:1480–1492.
102. Rotte A: Combination of CTLA-4 and PD-1 blockers for treatment of cancer. *J Exp Clin Cancer Res* 2019;38:255.
103. Hegde NR, Rao PP, Bayry J, and Kaveri SV: Immunotherapy of viral infections. *Immunotherapy* 2009;1: 691–711.
104. Hashimoto K, and Hosoya M: Neutralizing epitopes of RSV and palivizumab resistance in Japan. *Fukushima J Med Sci* 2017;63:127–134.
105. Schickli JH, Whitacre DC, Tang RS, Kaur J, Lawlor H, Peters CJ, Jones JE, Peterson DL, McCarthy MP, Van Nest G, and Milich DR: Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge. *J Clin Invest* 2015;125:1637–1647.
106. IMpact-RSV-Study-Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. *Pediatrics* 1998;102:531–537.
107. Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, Ploquin A, Doria-Rose NA, Staupé RP, Bailey M, Shi W, Choe M, Marcus H, Thompson EA, Cagigi A, Silacci C, Fernandez-Rodriguez B, Perez L, Sallusto F, Vanzetta F, Agatic G, Camerani E, Kisalu N, Gordon I, Ledgerwood JE, Mascola JR, Graham BS, Muyembe-Tamfun JJ, Trefry JC, Lanzavecchia A, and Sullivan NJ: Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. *Science* 2016; 351:1339–1342.
108. Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion R, Jr., Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, and Kyrtatsous CA: Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates. *J Infect Dis* 2018; 218:S612–S626.
109. Yang L, Liu W, Yu X, Wu M, Reichert JM, and Ho M: COVID-19 antibody therapeutics tracker: A global online database of antibody therapeutics for the prevention and treatment of COVID-19. *Antib Ther* 2020;3:205–212.
110. Gaudinski MR, Coates EE, Novik L, Widge A, Houser KV, Burch E, Holman LA, Gordon IJ, Chen GL, Carter C, Nason M, Sitar S, Yamshchikov G, Berkowitz N, Andrews C, Vazquez S, Laurentot C, Misasi J, Arnold F, Carlton K, Lawlor H, Gall J, Bailer RT, McDermott A, Capparelli E, Koup RA, Mascola JR, Graham BS, Sullivan NJ, and Ledgerwood JE: Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): An open-label phase 1 study. *Lancet* 2019;393:889–898.
111. Sivapalasingam S, Kamal M, Slim R, Hosain R, Shao W, Stoltz R, Yen J, Pologe LG, Cao Y, Partridge M, Sumner G, and Lipsich L: Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: A randomised, first-in-human phase 1 study. *Lancet Infect Dis* 2018;18:884–893.
112. Mulangu S, Dodd LE, Davey RT, Jr., Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfun JJ, Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolkis M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Vallee D, and Nordwall J: A randomized, controlled trial of Ebola virus disease therapeutics. *N Engl J Med* 2019; 381:2293–2303.
113. Davey RT, Jr., Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, and Malvy D: A randomized, controlled trial of ZMapp for Ebola virus infection. *N Engl J Med* 2016;375:1448–1456.
114. Choi JH, Woo HM, Lee TY, Lee SY, Shim SM, Park WJ, Yang JS, Kim JA, Yun MR, Kim DW, Kim SS, Zhang Y, Shi W, Wang L, Graham BS, Mascola JR, Wang N, McLellan JS, Lee JY, and Lee H: Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus. *PLoS One* 2020; 15:e0232757.
115. Corti D, Zhao J, Pedotti M, Simonelli L, Agnihotram S, Fett C, Fernandez-Rodriguez B, Foglierini M, Agatic G, Vanzetta F, Gopal R, Langrish CJ, Barrett NA, Sallusto F, Baric RS, Varani L, Zambon M, Perlman S, and Lanzavecchia A: Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. *Proc Natl Acad Sci U S A* 2015;112:10473–10478.
116. de Wit E, Feldmann F, Horne E, Okumura A, Camerani E, Haddock E, Saturday G, Scott D, Gopal R, Zambon M, Corti D, and Feldmann H: Prophylactic efficacy of a

- human monoclonal antibody against MERS-CoV in the common marmoset. *Antiviral Res* 2019;163:70–74.
117. de Wit E, Feldmann F, Okumura A, Horne E, Haddock E, Saturday G, Scott D, Erlandson KJ, Stahl N, Lipsich L, Kyratsous CA, and Feldmann H: Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. *Antiviral Res* 2018;156:64–71.
 118. Johnson RF, Bagci U, Keith L, Tang X, Mollura DJ, Zeitlin L, Qin J, Huzella L, Bartos CJ, Bohorova N, Bohorov O, Goodman C, Kim DH, Paulty MH, Velasco J, Whaley KJ, Johnson JC, Pettitt J, Ork BL, Solomon J, Oberlander N, Zhu Q, Sun J, Holbrook MR, Olinger GG, Baric RS, Hensley LE, Jahrling PB, and Marasco WA: 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. *Virology* 2016;490:49–58.
 119. Du L, Zhao G, Yang Y, Qiu H, Wang L, Kou Z, Tao X, Yu H, Sun S, Tseng CT, Jiang S, Li F, and Zhou Y: A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. *J Virol* 2014;88:7045–7053.
 120. Li Y, Wan Y, Liu P, Zhao J, Lu G, Qi J, Wang Q, Lu X, Wu Y, Liu W, Zhang B, Yuen KY, Perlman S, Gao GF, and Yan J: A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. *Cell Res* 2015;25:1237–1249.
 121. Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, Hunt C, Strein J, Berrebi A, Sisk JM, Matthews KL, Babb R, Chen G, Lai KM, Huang TT, Olson W, Yancopoulos GD, Stahl N, Frieman MB, and Kyratsous CA: Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. *Proc Natl Acad Sci U S A* 2015;112:8738–8743.
 122. Widjaja I, Wang C, van Haperen R, Gutierrez-Alvarez J, van Dieren B, Okba NMA, Raj VS, Li W, Fernandez-Delgado R, Grosveld F, van Kuppeveld FJM, Haagmans BL, Enjuanes L, Drabek D, and Bosch BJ: Towards a solution to MERS: Protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. *Emerg Microbes Infect* 2019;8:516–530.
 123. Jiang L, Wang N, Zuo T, Shi X, Poon KM, Wu Y, Gao F, Li D, Wang R, Guo J, Fu L, Yuen KY, Zheng BJ, Wang X, and Zhang L: Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. *Sci Transl Med* 2014;6:234ra259.
 124. Tang XC, Agnihothram SS, Jiao Y, Stanhope J, Graham RL, Peterson EC, Avnir Y, Tallarico AS, Sheehan J, Zhu Q, Baric RS, and Marasco WA: Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. *Proc Natl Acad Sci U S A* 2014;111:E2018–E2026.
 125. Ying T, Du L, Ju TW, Prabakaran P, Lau CC, Lu L, Liu Q, Wang L, Feng Y, Wang Y, Zheng BJ, Yuen KY, Jiang S, and Dimitrov DS: Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. *J Virol* 2014;88:7796–7805.
 126. NIH: A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051, 2017. <https://clinicaltrials.gov/ct2/show/NCT03301090>.
 127. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, Lu L, Jiang S, Yang Z, Wu Y, and Ying T: Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. *Emerg Microbes Infect* 2020;9:382–385.
 128. Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus A, van Kuppeveld FJM, Haagmans BL, Grosveld F, and Bosch BJ: A human monoclonal antibody blocking SARS-CoV-2 infection. *Nat Commun* 2020;11:2251.
 129. Chen X, Li R, Pan Z, Qian C, Yang Y, You R, Zhao J, Liu P, Gao L, Li Z, Huang Q, Xu L, Tang J, Tian Q, Yao W, Hu L, Yan X, Zhou X, Wu Y, Deng K, Zhang Z, Qian Z, Chen Y, and Ye L: Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. *Cell Mol Immunol* 2020;17:647–649.
 130. Noy-Porat T, Makdasi E, Alcalay R, Mechaly A, Levy Y, Bercovich-Kinori A, Zauberman A, Tamir H, Yahalom-Ronen Y, Israeli M, Epstein E, Achdout H, Melamed S, Chitlaru T, Weiss S, Peretz E, Rosen O, Paran N, Yitzhaki S, Shapira SC, Israely T, Mazor O, and Rosenfeld R: A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. *Nat Commun* 2020;11:4303.
 131. Yuan M, Wu NC, Zhu X, Lee CD, So RTY, Lv H, Mok CKP, and Wilson IA: A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. *Science* 2020;368:630–633.
 132. Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, Song T, Bi X, Han C, Wu L, Gao G, Hu X, Zhang Y, Tong Z, Huang W, Liu WJ, Wu G, Zhang B, Wang L, Qi J, Feng H, Wang FS, Wang Q, Gao GF, Yuan Z, and Yan J: A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. *Nature* 2020;584:120–124.
 133. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Lan J, Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu L, Zhao J, Wang X, Zhang Z, and Zhang L: Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature* 2020;584:115–119.
 134. Lv Z, Deng YQ, Ye Q, Cao L, Sun CY, Fan C, Huang W, Sun S, Sun Y, Zhu L, Chen Q, Wang N, Nie J, Cui Z, Zhu D, Shaw N, Li XF, Li Q, Xie L, Wang Y, Rao Z, Qin CF, and Wang X: Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. *Science* 2020;369:1505–1509.
 135. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, Mills R, Teng E, Kamruzzaman M, Garcia-Beltran WF, Astudillo M, Yang D, Miller TE, Oliver E, Fischinger S, Atyeo C, Iafrate AJ, Calderwood SB, Lauer SA, Yu J, Li Z, Feldman J, Hauser BM, Caradonna TM, Branda JA, Turbett SE, LaRocque RC, Mellon G, Barouch DH, Schmidt AG, Azman AS, Alter G, Ryan ET, Harris JB, and Charles RC: Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. *Sci Immunol* 2020;5:eabe0367.
 136. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, Chen Z, Guo Y, Zhang J, Li Y, Song X, Chen Y, Xia L, Fu L, Hou L, Xu J, Yu C, Li J, Zhou Q, and Chen W: A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science* 2020;369:650–655.

137. Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L, and Ho DD: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature* 2020;584:450–456.
138. Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De Marco A, Peter A, Guarino B, Spreafico R, Cameroni E, Case JB, Chen RE, Havenar-Daughton C, Snell G, Telenti A, Virgin HW, Lanzavecchia A, Diamond MS, Fink K, Veelsler D, and Corti D: Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* 2020; 583:290–295.
139. Golsaz Shirazi F, Mohammadi H, Amiri MM, Singethan K, Xia Y, Bayat AA, Bahadori M, Rabbani H, Jedditehrani M, Protzer U, and Shokri F: Monoclonal antibodies to various epitopes of hepatitis B surface antigen inhibit hepatitis B virus infection. *J Gastroenterol Hepatol* 2014;29:1083–1091.
140. Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, Fulton BO, Yan Y, Koon K, Patel K, Chung KM, Hermann A, Ullman E, Cruz J, Rafique A, Huang T, Fairhurst J, Libertiny C, Malbec M, Lee WY, Welsh R, Farr G, Pennington S, Deshpande D, Cheng J, Watty A, Bouffard P, Babb R, Levenkova N, Chen C, Zhang B, Romero Hernandez A, Saotome K, Zhou Y, Franklin M, Sivapalasingam S, Lye DC, Weston S, Logue J, Haupt R, Frieman M, Chen G, Olson W, Murphy AJ, Stahl N, Yancopoulos GD, and Kyratsous CA: Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science* 2020;369:1010–1014.
141. Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K, Negron N, Ni M, Wei Y, Atwal GS, Murphy AJ, Stahl N, Yancopoulos GD, and Kyratsous CA: Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. *Science* 2020;369:1014–1018.
142. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, Perry C, Pan C, Hosain R, Mahmood A, Davis JD, Turner KC, Hooper AT, Hamilton JD, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Kohli A, Sachdeva Y, Graber X, Kowal B, DiCioccio T, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, and Trial I: REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. *N Engl J Med* 2020;384:238–251.
143. Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schafer A, Reidy JX, Trivette A, Nargi RS, Sutton RE, Suryadevara N, Martinez DR, Williamson LE, Chen EC, Jones T, Day S, Myers L, Hassan AO, Kafai NM, Winkler ES, Fox JM, Shrihari S, Mueller BK, Meiler J, Chandrashekar A, Mercado NB, Steinhardt JJ, Ren K, Loo YM, Kallewaard NL, McCune BT, Keeler SP, Holtzman MJ, Barouch DH, Gralinski LE, Baric RS, Thackray LB, Diamond MS, Carnahan RH, and Crowe JE, Jr.: Potently neutralizing and protective human antibodies against SARS-CoV-2. *Nature* 2020;584:443–449.
144. Zost SJ, Gilchuk P, Chen RE, Case JB, Reidy JX, Trivette A, Nargi RS, Sutton RE, Suryadevara N, Chen EC, Binshtein E, Shrihari S, Ostrowski M, Chu HY, Didier JE, MacRenaris KW, Jones T, Day S, Myers L, Eun-Hyung Lee F, Nguyen DC, Sanz I, Martinez DR, Rothlauf PW, Bloyet LM, Whelan SPJ, Baric RS, Thackray LB, Diamond MS, Carnahan RH, and Crowe JE, Jr.: Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. *Nat Med* 2020;26:1422–1427.
145. Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, and Griffin MP: A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. *Antimicrob Agents Chemother* 2013;57:6147–6153.
146. Griffin MP, Khan AA, Esser MT, Jensen K, Takas T, Kankam MK, Villafana T, and Dubovsky F: Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. *Antimicrob Agents Chemother* 2017;61:e01714-16.
147. Yu XQ, Robbie GJ, Wu Y, Esser MT, Jensen K, Schwartz HI, Bellamy T, Hernandez-Illas M, and Jafri HS: Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults. *Antimicrob Agents Chemother* 2017;61:e01020-16.
148. Kim C, Ryu DK, Lee J, Kim YI, Seo JM, Kim YG, Jeong JH, Kim M, Kim JI, Kim P, Bae JS, Shim EY, Lee MS, Kim MS, Noh H, Park GS, Park JS, Son D, An Y, Lee JN, Kwon KS, Lee JY, Lee H, Yang JS, Kim KC, Kim SS, Woo HM, Kim JW, Park MS, Yu KM, Kim SM, Kim EH, Park SJ, Jeong ST, Yu CH, Song Y, Gu SH, Oh H, Koo BS, Hong JJ, Ryu CM, Park WB, Oh MD, Choi YK, and Lee SY: A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. *Nat Commun* 2021;12:288.
149. Ison MG: Therapeutic Effect of Regdanvimab (CT-P59) in Patients with Mild to Moderate Symptoms of SARS CoV 2 Infection: eSymposia, Antibodies and Vaccines as Drugs for COVID-19, Virtual Key Stone Symposia, 2021. <https://virtual.keystonesymposia.org/ks/sessions/6866/view>. (Accessed January 16, 2021).
150. Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, Wiethoff CM, Blackburne JL, Heinz BA, Foster D, Higgs RE, Balasubramanian D, Wang L, Bidshahri R, Kraft L, Hwang Y, Zentelis S, Jepson KR, Goya R, Smith MA, Collins DW, Hinshaw SJ, Tycho SA, Pellacani D, Xiang P, Muthuraman K, Sobhanifar S, Piper MH, Triana FJ, Hendle J, Pustilnik A, Adams AC, Berens SJ, Baric RS, Martinez DR, Cross RW, Geisbert TW, Borisevich V, Abiona O, Belli HM, de Vries M, Mohamed A, Dittmann M, Samanovic M, Mulligan MJ, Goldsmith JA, Hsieh CL, Johnson NV, Wrapp D, McLellan JS, Barnhart BC, Graham BS, Mascola JR, Hansen CL, and Falconer E: LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. *bioRxiv* 2020. Doi: 10.1101/2020.09.30.318972.
151. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, Shawa I, Adams AC, Van Naarden J, Custer KL, Shen L, Durante M, Oakley G, Schade AE, Sabo J, Patel DR, Klekotka P, Skovronsky DM, and Investigators B-: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. *N Engl J Med* 2021;384:229–237.
152. Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, Shawa I, Kumar P, Adams AC, Van Naarden J, Custer KL, Durante

- M, Oakley G, Schade AE, Holzer TR, Ebert PJ, Higgs RE, Kallewaard NL, Sabo J, Patel DR, Klekotka P, Shen L, and Skovronsky DM: Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial. *JAMA* 2021;325, DOI: 10.1001/jama.2021.0202.
153. Fala L: Portrazza (necitumumab), an IgG1 monoclonal antibody, FDA approved for advanced squamous non-small-cell lung cancer. *Am Health Drug Benefits* 2016;9: 119–122.
 154. Garcia-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P, and Stintzing S: Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors. *Front Oncol* 2019;9:849.
 155. Dubois EA, and Cohen AF: Panitumumab. *Br J Clin Pharmacol* 2009;68:482–483.
 156. Crombet Ramos T, Mestre Fernandez B, Mazorra Herrera Z, and Iznaga Escobar NE: Nimotuzumab for patients with inoperable cancer of the head and neck. *Front Oncol* 2020;10:817.
 157. Kazazi-Hyseni F, Beijnen JH, and Schellens JH: Bevacizumab. *Oncologist* 2010;15:819–825.
 158. Wu J, Fu J, Zhang M, and Liu D: Blinatumomab: A bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. *J Hematol Oncol* 2015;8:104.
 159. Rizzieri D: Zevalin((R)) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned? *Crit Rev Oncol Hematol* 2016;105:5–17.
 160. Weiner GJ: Rituximab: Mechanism of action. *Semin Hematol* 2010;47:115–123.
 161. Biodrugs: Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab. *BioDrugs* 2003;17:290–295.
 162. Zhang B: Ofatumumab. *MAbs* 2009;1:326–331.
 163. Tobinai K, Klein C, Oya N, and Fingerle-Rowson G: A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. *Adv Ther* 2017;34:324–356.
 164. Lambert J, Pautas C, Terre C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, and Castaigne S: Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. *Haematologica* 2019; 104:113–119.
 165. Sanchez L, Wang Y, Siegel DS, and Wang ML: Daratumumab: A first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. *J Hematol Oncol* 2016;9:51.
 166. Havrdova E, Horakova D, and Kovarova I: Alemtuzumab in the treatment of multiple sclerosis: Key clinical trial results and considerations for use. *Ther Adv Neurol Disord* 2015;8:31–45.
 167. Gemmete JJ, and Mukherji SK: Trastuzumab (herceptin). *AJNR Am J Neuroradiol* 2011;32:1373–1374.
 168. McDermott J, and Jimeno A: Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. *Drugs Today (Barc)* 2015;51:7–20.
 169. Guo L, Zhang H, and Chen B: Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. *J Cancer* 2017;8:410–416.
 170. Gil-Bazo I: Avelumab-a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer. *Transl Lung Cancer Res* 2017;6:S35–S38.
 171. Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, and Drakaki A: Durvalumab: An investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. *Drug Des Devel Ther* 2018;12:209–215.
 172. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, and Heo YS: Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. *Sci Rep* 2017;7:5532.
 173. Magen H, and Muchtar E: ELOTUZUMAB: The first approved monoclonal antibody for multiple myeloma treatment. *Ther Adv Hematol* 2016;7:187–195.
 174. Dhillon S: Dinutuximab: First global approval. *Drugs* 2015;75:923–927.
 175. Tarhini A, Lo E, and Minor DR: Releasing the brake on the immune system: Ipilimumab in melanoma and other tumors. *Cancer Biother Radiopharm* 2010;25:601–613.

Address correspondence to:

Nagendra R. Hegde
National Institute of Animal Biotechnology
Opp. Journalist Colony, Extended Q City Road,
Near Gowlidoddi, Gachibowli
Hyderabad 500032
India

E-mail: hegde@niab.org.in

Received: February 7, 2021
Accepted: February 26, 2021